NCT02953717
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 11-20 newly diagnosed brain metastases on a triple dose gadolinium-enhanced MRI-scan
Exclusions: Patients with progressive or symptomatic disease; Patients with leptomeningeal disease; Patients with prior brain radiation or surgical resection of brain metastases
https://ClinicalTrials.gov/show/NCT02953717